Supernus Pharmaceuticals Inc (SUPN)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 19.79% | 32.39% | 29.06% | 30.64% | 30.55% | 24.89% | 28.68% | 29.24% | 31.72% | 37.56% | 40.83% | 46.29% | 48.95% | 61.03% | 64.04% | 65.46% | 65.26% | 66.58% | 66.69% | 66.57% |
| Operating profit margin | -0.71% | 4.85% | 3.18% | 7.31% | 6.85% | 2.75% | 8.41% | 12.77% | 15.36% | 22.56% | 26.56% | 29.43% | 34.28% | 36.85% | 37.06% | 37.83% | 37.83% | 36.16% | 35.53% | 34.28% |
| Pretax margin | 0.46% | 5.96% | 4.14% | 8.15% | 9.02% | 4.25% | 9.23% | 13.14% | 13.07% | 20.33% | 24.40% | 28.06% | 33.28% | 36.50% | 37.46% | 37.86% | 37.55% | 35.60% | 34.74% | 32.98% |
| Net profit margin | 0.02% | 4.14% | 6.76% | 7.71% | 9.02% | 5.78% | 9.30% | 12.52% | 9.54% | 15.00% | 18.17% | 20.71% | 25.05% | 27.79% | 28.24% | 28.90% | 28.79% | 25.92% | 25.66% | 25.49% |
The profitability ratios of Supernus Pharmaceuticals Inc show some fluctuations over the past eight quarters. The gross profit margin has generally remained high, ranging from 85.27% to 88.34%, indicating the company's ability to generate profit from its core business operations.
However, the operating profit margin has varied more significantly, with values ranging from 2.21% to 11.29%. This suggests that the company's operating expenses may have fluctuated over this period, impacting its operational efficiency.
Similarly, the pretax margin and net profit margin have also shown fluctuations, with values ranging from 0.22% to 12.80% for pretax margin and from 0.22% to 12.20% for net profit margin. These margins reflect the company's ability to generate profits after accounting for all expenses, including taxes.
Overall, while Supernus Pharmaceuticals Inc has demonstrated a strong gross profit margin, its operating efficiency and bottom-line profitability have been more volatile. It would be prudent for stakeholders to further investigate the reasons behind these fluctuations to assess the company's long-term profitability sustainability.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -427,300.00% | 2.34% | 1.58% | 2.75% | 2.71% | 1.06% | 3.07% | 4.56% | 5.09% | 7.91% | 9.31% | 10.47% | 11.55% | 11.36% | 10.40% | 12.79% | 12.80% | 13.34% | 13.67% | 13.50% |
| Return on assets (ROA) | 14,100.00% | 1.99% | 3.35% | 2.90% | 3.57% | 2.22% | 3.39% | 4.47% | 3.16% | 5.26% | 6.37% | 7.37% | 8.44% | 8.56% | 7.93% | 9.77% | 9.74% | 9.56% | 9.87% | 10.04% |
| Return on total capital | 419,400.00% | 4.22% | 3.25% | 6.50% | — | 4.14% | 8.19% | 7.53% | 7.77% | 10.98% | 13.32% | 15.20% | 17.00% | 17.70% | 17.19% | 17.70% | 17.62% | 18.55% | 18.86% | 18.72% |
| Return on equity (ROE) | 14,100.00% | 2.81% | 4.71% | 5.71% | — | 4.42% | 6.83% | 8.85% | 6.55% | 10.09% | 12.75% | 14.73% | 17.04% | 18.24% | 17.74% | 18.95% | 18.99% | 18.99% | 20.07% | 21.45% |
Supernus Pharmaceuticals Inc's profitability ratios have shown fluctuating trends over the past eight quarters. In terms of operating profitability, the operating return on assets (Operating ROA) has ranged from 1.05% to 4.14%, with a downward trend in recent quarters. This indicates that the company's operating efficiency has generally been decreasing.
When looking at the overall profitability of the company, the return on assets (ROA) has varied between 0.10% and 4.47%. There is inconsistency in performance, with ROA peaking in Q2 2023 and hitting a low point in Q1 2022. This suggests that while the company has had periods of strong profitability, there have been quarters with subpar performance.
The return on total capital has also shown fluctuations, ranging from 1.45% to 5.53%. This metric combines both operating and financial efficiency, indicating the company's ability to generate returns from investments in both assets and debt. The downward trend in the most recent quarters may raise concerns about the company's capital utilization.
Lastly, the return on equity (ROE) has displayed a similar pattern, varying from 0.14% to 8.85%. ROE reflects how well the company is utilizing shareholders' equity to generate profits. The significant swings in ROE suggest that Supernus Pharmaceuticals Inc's ability to generate returns for its shareholders has been inconsistent.
Overall, Supernus Pharmaceuticals Inc's profitability ratios indicate a lack of consistent profitability, with fluctuating performance across different measures over the past two years. Further analysis and investigation may be needed to identify the underlying reasons for the variability in these ratios and to develop strategies to improve the company's overall profitability.